Government spending on antiretrovirals in Brazil and its main determinants

• Autor(a) principal: Zucoloto, Graziela Ferrero
• Data de Publicação: 2023
• Outros Autores: Scopel, Carolinne Thays, Villardi, Pedro, Fonseca, Felipe de Carvalho Borges da, Ploeg, Susana Rodrigues Cavalcanti van der, Szigethy, Leonardo
• Tipo de documento: preprint
• Idioma: por
• Título da fonte: SciELO Preprints
• Texto Completo: https://preprints.scielo.org/index.php/scielo/preprint/view/6303
• topic: Antirretrovirais; HIV; Preço de Medicamento; Propriedade Intelectual de Produtos e Processos Farmacêuticos; Anti-Retroviral Agents; HIV; Drug Price; Intellectual Property of Pharmaceutic Products and Process

The construction of public policies for the prevention and treatment of HIV/AIDS in Brazil is a history of struggle that unites sanitarians, researchers and activists since the 1980s. An important part of this path is linked to the production and distribution of antiretroviral drugs (ARV), initiatives to reduce the price of ARVs and civil society mobilizations for the guarantee of rights, which contributed to create one of the most successful programs to combat the disease in the country. world. Based on this history, this study aimed to analyze government spending on the acquisition of selected ARVs in the period between 2005 and 2020, making a comparison with international prices, in the light of determinants related to patent disputes, voluntary licensing, PDPs and ARV price reduction initiatives. Among other results, it was possible to observe that there was no immediate relationship between the end of the patent concession and the reduction of prices. Filings of other patent applications and the lack of nationally registered competitors, even after patent expiration, can be significant factors in maintaining high prices.